Thursday, 17 Aug 2017

You are here

Above-Label Dosing and Noncompliance with Biologics in Psoriatic Arthritis

In this era of treat-to-target or remission targeted therapeutics, the options in managing nonresponders are many; often including off-label doses (i.e., dose escalations or reduction, increasing frequency; interrupted treatment). The use of above-label dosing, and its' effect on drug costs, has seldom been studied. 

Schwartzman and colleagues have studied biologic utilization in psoriatic arthritis (PsA), and the economic impact of increased doses, specifically looking at costs associated with above-label dosing and noncompliance with biologics in PsA.

Using MarketScan claims data they analyzed the first biologic claim with a 1-year follow-up period. The duration of use was stratified into three groups: <30, 30–179, and ≥180 days and defined above-label dosing as >10% of the labeled dose. They analyzed 4245 PsA patients treated with common biolgics (etanercept; n = 2342 ; adalimumab 1788, golimumab 115) between 2011 - 2013.

Above-label dosing for  <30 days was common and seen in 85% of adalimumab, 90.4% of etanercept, and 95.7% of golimumab patients. Longer term (≥180 days) was less common  (9.6% adalimumab, 4.1% etanercept, and 2.6% golimumab).

The mean number of days of on-label use ranged from 267 (adalimumab) to 295 (golimumab).

The mean number of days of above-label use was lowest with golimumab (12 days) and highest with adalimumab (35 days). Etanercept days of above-label use was 17  days.

Noncompliance could be inferred by no-use or below-label use days.  Below-label use was onlyreported for etanercept (4days) and adalimumab (1 day). No use was significantly higher for etanercept (71 days), compared to adalimumab (63 days), and golimumab (59 days).

All-cause total healthcare costs rose substantially with above-label use (p < 0.05).

These analyses suggest noncompliance with biologics is very common and that above-label use of anti-TNF biologics not only occurs, but is associated with significantly increased healthcare costs.

The clinical consequences or associations of these off-label dosing practices could not be studied in this claims dataset.

Dr. Schwartman collaborated with Novartis to perform these studies.

 

Disclosures: 
The author has received research/grant financial support on this subject
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Psoriatic Arthritis Patients with Comorbidities have Worse Disease and Poor Responses

A population-based cohort study shows that comorbidities in psoriatic arthritis patients (PsA) were associated with higher disease activity, shorter persistence and reduced clinical response to TNF inhibitors (TNFi). 

FDA Arthritis Advisory Panel Endorses Tofacitinib Approval for Psoriatic Arthritis

On Thursday, August 3, the FDA Arthritis Advisory Committee (AAC) met to consider tofacitinib for use in patients with psoriatic arthritis. The panel voted 10-1 in favor of approval.

Pediatric Consensus on Comorbidity Assessments

Comorbidity is a serious consequence or confounder in patients with inflammatory diseases. This has been well described in both psoriatic and rheumatoid disease.  JAMA Dermatology has published the recommendations of a pediatric multispecialty group regarding the screening for comorbid disease. (Citation source https://buff.ly/2u4pi3J)

Obesity Impairs TNF Inhibitor Responses in Axial Spondyloarthritis

Investigators with the Swiss Clinical Quality Management (SCQM) program have studied the effects of obesity on patients with axial spondyloarthritis (axSpA) and, specifically, their response to tumor necrosis factor inhibitors (TNFi).

FDA Approves Tremfya (guselkumab) for Plaque Psoriasis

The U.S. Food and Drug Administration (FDA) has approved the IL-23 inhibitor, Tremfya (guselkumab), for patients with moderate to severe plaque psoriasis.